Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24047115 | 0.88 | NR4A2 (0.73) | NR4A1NR4A2NR4A3PKMPARP10 | |
| SCHEMBL5727237 | 0.86 | SRD5A2 (0.65) | NR4A1NR4A2NR4A3PKMPARP10 | |
| SCHEMBL228290 | 0.85 | NR4A2 (0.74) | NR4A1NR4A2NR4A3PARP10MAOB | |
| SCHEMBL6378011 | 0.85 | SRD5A2 (0.63) | NR4A1NR4A2NR4A3PKMPARP10 | |
| SCHEMBL2984321 | 0.85 | MAOB (0.74) | NR4A1NR4A2NR4A3PKMPARP10 | |
| SCHEMBL6375370 | 0.84 | SRD5A2 (0.58) | NR4A1NR4A2NR4A3PKMPARP10 | |
| SCHEMBL7550951 | 0.84 | NR4A1 (0.54) | NR4A1NR4A2NR4A3PKMPARP10 | |
| SCHEMBL17239661 | 0.84 | NR4A1 (0.54) | NR4A1NR4A2NR4A3PKMPARP10 | |
| SCHEMBL22815873 | 0.84 | MAPT (0.53) | PKMPARP10MAPTRAB9AKDM4E | |
| SCHEMBL19612666 | 0.83 | FFAR1 (0.64) | NR4A1NR4A2NR4A3PKMPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ONCOLYS BIOPHARMA, INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ONCOLYS BIOPHARMA, INC. (JP) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ACE2, ACE, SARS1 | NR4A1 4485/4885NR4A2 3880/4885NR4A3 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.